Clinical trial
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic…
NCT00288041 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00288041 |
|---|---|
| Title | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma |
| Official title | A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for the Treatment of Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Drug |
| Interventions | carboplatin, paclitaxel, bortezomib |
| Enrollment | 36 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 1, 2007 |
| First posted | Feb 7, 2006 |
| Last update posted | Mar 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: